SG001 (ENLONSTOBART) is an innovative monoclonal antibody therapeutic biological candidate developed by Sumgen. The application for market approval was accepted by the NMPA in March 2023, and it has been granted conditional approval indicated for the treatment of malignant tumors.
Copyright Rm. 301, F3, Building C, Block 2, No. 688, Bin'an Road, Changhe Zhejiang ICP Filing No. 18039044
